Clinical Trial

An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Dimensions: NCT02219490

Investigators

Affiliations

Organisations

  1. (1) AbbVie (United States), grid.431072.3

Sponsors/collaborators

Abstract

The purpose of this study is to evaluate Long-term outcomes following treatment with ABT-450/r/ABT-267 and ABT-333 with or without RBV in adults with genotype 1 Chronic Hepatitis C Virus (HCV) infection.

Methods

Condition: Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Intervention: tablet

Recruitment information

Gender: All

Trial period

2014-2021

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry